nemolizumab (Mitchga)
Jump to navigation
Jump to search
Indications
- treatment of prurigo nodularis
- treatment of moderate-severe atopic dermatitis
Adverse effects
- serious treatment-emergent adverse events in < 3%
Mechanism of action
- monoclonal antibody inhibiting IL-31 receptor alpha
More general terms
References
- ↑ Silverberg JI, Wollenberg A, Reich A, et al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. Lancet. 2024 Jul 24:S0140-6736(24)01203-0 PMID: https://www.ncbi.nlm.nih.gov/pubmed/39067461